Genmab

$31.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.83 (+2.68%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Genmab and other stocks, options, and ETFs commission-free!

About GMAB

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark. The listed name for GMAB is Genmab A/S ADS.

CEO
Jan G. J. van de Winkel
Employees
781
Headquarters
Copenhagen, Capital Region
Founded
1999
Market Cap
22.10B
Price-Earnings Ratio
28.44
Dividend Yield
—
Average Volume
1.07M
High Today
$31.76
Low Today
$30.18
Open Price
$31.48
Volume
1.01M
52 Week High
$44.83
52 Week Low
$16.24

GMAB Earnings

$0.00
$2.53
$5.05
$7.58
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$1.17 per share
Actual
$1.41 per share
Replay Earnings Call

You May Also Like

XCEM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure